Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis

ConclusionsInsufficient data exist to quantify or distinguish the risk of acute vs chronic enterocolitis following ipilmumab use. Because of the serious impact of chronic enterocolitis on quality of life and further cancer treatment, future trials evaluating the safety of immunotherapy should report gastrointestinal events in greater detail.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research